This started with
a dog named
Loulou.
Our labradoodle Loulou is nine years old. She was diagnosed with bone cancer. What followed was the hardest period our family has ever been through — not just the fear of losing her, but the feeling of standing at the edge of something vast and dark, with no map and no guide.
Three veterinary clinics. Three oncology specialists. Three rounds of CT scans. Each appointment ended the same way — with compassion, with honesty, but without a clear path forward. The medicine existed in fragments. The data existed in silos. Nothing connected detection to treatment to action in a way that felt like it was designed for Loulou, for her breed, for her exact biology.
Then I came across a story about a tech entrepreneur in Australia. His dog had cancer. He wasn't a scientist. But he had access to the same tools everyone has — ChatGPT, AlphaFold, a network of researchers who were, as he described them, "all so excited" to help. Together they designed a custom mRNA vaccine. Within weeks of the first injection, the tumour had significantly reduced in size.
I sat with that story for a long time. It gave me something I hadn't had since Loulou's diagnosis: hope. But it also gave me something else — clarity about what was missing. That entrepreneur had done something extraordinary, but he had done it by hand. By instinct. By calling in favours and piecing together tools that were never designed to work together.
I had been building SeCore Information Security for years — a platform that takes something impossibly complex, cybersecurity risk, and turns it into a single precise number that tells you exactly where you stand and exactly what to do next. Professor Basel Katt, my co-founder and one of Europe's leading minds in quantitative security assurance, had spent a career proving that you can bring mathematical rigour to problems that feel unsolvable.
Sitting at my kitchen table the night after reading that Australian story, it became obvious: the mathematics are the same. Scoring the severity of a security vulnerability and scoring the immunological potential of a cancer vaccine candidate are, at their core, the same problem. Multi-signal inputs. Weighted criteria. A normalised output that tells a clinician — or a vet — exactly where to act first.
SeCore Biotech was not born in a boardroom. It was born in the space between a diagnosis and a question: what if the tools already exist — they just haven't been connected yet?
Loulou is still with us. Her diagnosis hasn't changed. But the reason we are building this platform, with the urgency we feel every single day, is because she deserves better than what the current system can offer — and so does every other dog whose owner is sitting in a clinic waiting room, hearing the same words we heard, and feeling the same weight we felt.
We are building the platform we wish had existed when Loulou was diagnosed.